Episode 185 - Ed Ahn - Medipost INC

Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modification.Edward leads MEDIPOST's U.S. operations and global expansion efforts for CARTISTEM®, the world's first approved allogeneic stem cell therapy derived from umbilical cord blood. Since its approval in South Korea, CARTISTEM has been used to treat more than 30,000 patients, and under Edward's leadership the company is now advancing late-stage clinical development in the United States, with one of the most ambitious regenerative medicine programs in orthopedics today.What makes Edward's perspective particularly interesting is his focus on the practical realities of turning breakthrough science into scalable healthcare solutions. He has championed a strategy that combines clinical development, manufacturing infrastructure, regulatory execution, and long-term commercialization planning from day one. That vision has included building a North American presence, forming strategic manufacturing partnerships, and creating the operational foundation required to bring advanced cell therapies to patients around the world.As regenerative medicine moves from promise to reality, Edward has become a leading voice on how biotechnology companies can successfully navigate the path from scientific innovation to global commercialization. His work sits at the intersection of stem cell science, healthcare innovation, manufacturing strategy, and venture-backed growth—areas that will define the next generation of medicine.